Furthermore, the effects of the NRP1 inhibitor on the in vivo growth and progression of PAAD were investigated using the orthotopic pancreatic tumor-bearing nude (immunodeficient) and C57BL/6 (immunocompetent) mouse models (Figure 7). Here, NRP1 is linked to pancreatic neoplasm.